This website is best viewed using the vertical display on your mobile device.
In the DASISION Trial
AR=adverse reaction; CNS=central nervous system; CP=chronic phase.
*Includes cardiac failure acute, cardiac failure congestive, cardiomyopathy, diastolic dysfunction, ejection fraction decreased, and left ventricular dysfunction.1
†Includes erythema, erythema multiforme, rash, rash generalized, rash macular, rash papular, rash pustular, skin exfoliation, and rash vesicular.1
‡Adverse reaction of special interest with <10% frequency.1
§Includes conjunctival hemorrhage, ear hemorrhage, ecchymosis, epistaxis, eye hemorrhage, gingival bleeding, hematoma, hematuria, hemoptysis, intra-abdominal hematoma, petechiae, scleral hemorrhage, uterine hemorrhage, and vaginal hemorrhage.1
Get a quick summary of key SPRYCEL efficacy, safety, and dosing information
Low discontinuation rates associated with myelosuppression1
No SPRYCEL-treated patients discontinued therapy due to changes in biochemical laboratory parameters1
SPRYCEL offers a known and consistent adverse reaction profile (AR ≥10%) over the long term through
Year 5 in the DASISION Trial.1
CTC grades: neutropenia (Grade 3 ≥0.5-<1.0 x 109/L, Grade 4 <0.5 x 109/L); thrombocytopenia (Grade 3 ≥25-<50 x 109/L, Grade 4 <25 x 109/L); anemia (hemoglobin Grade 3 ≥65-<80 g/L, Grade 4 <65 g/L); elevated creatinine (Grade 3 >3-6 x upper limit of normal range [ULN], Grade 4 >6 x ULN); elevated bilirubin (Grade 3 >3-10 x ULN, Grade 4 >10 x ULN); elevated SGOT or SGPT (Grade 3 >5-20 x ULN, Grade 4 >20 x ULN); hypocalcemia (Grade 3 <7.0-6.0 mg/dL, Grade 4 <6.0 mg/dL); hypophosphatemia (Grade 3 <2.0-1.0 mg/dL, Grade 4 <1.0 mg/dL); hypokalemia (Grade 3 <3.0-2.5 mmol/L, Grade 4 <2.5 mmol/L).
ALT=alanine aminotransferase; AST=aspartate aminotransferase; CP=chronic phase; CTC=Common Terminology Criteria; SGOT=serum glutamic-oxaloacetic transaminase; SGPT=serum glutamic-pyruvic transaminase; ULN=upper limit of normal.
SPRYCEL may increase the risk of prolongation of QTc in patients including those with hypokalemia or hypomagnesemia, patients with congenital long QT syndrome, patients taking antiarrhythmic medicines or other medicinal products that lead to QT prolongation, and cumulative high-dose anthracycline therapy.